

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

Emend (aprepitant) Oral

Override(s)	Approval Duration
Prior Authorization Quantity Limits	1 year

Medications	Quantity Limit
Emend (aprepitant) 125 mg (25 mg/mL) oral suspension single-dose kit	Maybe subject to quantity limit
Emend (aprepitant) TriPack (3 capsules – one-125 mg capsule and two-80 mg capsules)	
Emend (aprepitant) 40mg, 80mg, 125mg capsules	

APPROVAL CRITERIA

Requests for an Emend (aprepitant) oral agent (capsules, suspension) may be approved when the following criteria are met:

- I. Individual is using to prevent acute or delayed nausea and vomiting associated with initial or repeat courses of one of the following:
 - A. Highly emetogenic cancer chemotherapy (HEC) [such as but not limited to, high-dose cisplatin, cyclophosphamide-doxorubicin, cyclophosphamide-epirubicin (NCCN 2019, ASCO 2011)] (Label, NCCN 1); **OR**
 - B. Moderately emetogenic cancer chemotherapy (MEC) [such as but not limited to carboplatin, daunorubicin, irinotecan (NCCN 2019, ASCO 2011)] (Label, NCCN 1, NCCN Antiemesis 1.2019);

AND

- II. Individual is using as part of a regimen that also includes the following;
 - A. A 5-HT3 Receptor antagonist in combination with a corticosteroid for adult individuals; **OR**
 - B. A 5-HT3 receptor antagonist alone OR in combination with a corticosteroid for pediatric individuals.

Requests for Emend (aprepitant) oral capsules may also be approved when the following criteria are met:

CRX-ALL-0526-20

PAGE 1 of 2 03/02/2020

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	NA

- I. Individual is 18 years of age or older; **AND**
- II. Individual is using to prevent postoperative nausea and vomiting (PONV).

Emend (aprepitant) oral agents (capsules, suspension) may **not** be approved for the following:

- I. Treatment of established nausea and vomiting; **OR**
- II. Chronic, continuous administration for nausea and vomiting; **OR**
- III. Concomitant use with pimozide (Orap).

Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: September 27, 2019.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
5. Basch E, Prestrud AA, Hesketh PJ, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 29:4189-4198 . DOI: 10.1200/JCO.2010.34.4614.
6. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on September 27, 2019.
 - a. Antiemesis. V1.2019. Revised February 28, 2019.
 - b. Palliative Care. V2.2019. Revised February 8, 2019

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.